# Cocrystal Pharma (COCP) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/COCP
## Company Profile
- Ticker: COCP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Infectious Disease
## Stock Data
- Close: 1.02 USD
- Market cap: 14476825.65 USD
- Last updated: 2026-08-05
## Business Overview
### Broad-Spectrum Antiviral Developer
Cocrystal Pharma uses a structure-based drug discovery platform to develop broad-spectrum antiviral medicines targeting conserved regions of viral proteases and polymerases. The strategy is intended to maintain activity across viral variants while minimizing off-target effects.
### CDI-988 Norovirus Program
CDI-988 is an oral antiviral candidate for norovirus being evaluated in a Phase 1b human challenge study conducted with Emory University and the University of North Carolina. The trial includes both prevention and treatment cohorts.
### Human Challenge Development Model
The controlled human infection study is designed to measure symptom incidence, viral shedding, safety, and pharmacokinetics in a defined setting. This approach can generate early proof-of-concept evidence for both prophylactic and therapeutic use.
### Influenza and Coronavirus Pipeline
CC-42344 is a PB2 inhibitor for pandemic and seasonal influenza A. Cocrystal is also developing an inhaled formulation and generating leads for influenza A and B, while CDI-988 may have applications in coronavirus infections.
## Why The Stock Is Moving

As of Aug 5, 2026, COCP closed up 4.06% at $1.02. No new same-company headline was identified in the current news window.

## Future Catalysts

- The CDI-988 Phase 1b human challenge study has completed the infectivity cohort and begun prevention and treatment cohorts; symptom incidence, viral shedding, safety, and pharmacokinetic results are the key upcoming readouts.
- An additional Phase 2a study of oral CC-42344 in influenza A is planned.

## Recent News
- 2026-08-03 11:00 EST — [Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health](https://biopharmsignal.com/news/COCP/cocrystal-pharma-announces-5-million-private-placement-with-opko-health-1279403a) — Source: Cocrystal Pharma
- 2026-06-03 11:00 EST — [Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer](https://biopharmsignal.com/news/COCP/cocrystal-pharma-appoints-james-sapirstein-biopharma-industry-leader-with-extens-347ef789) — Source: Cocrystal Pharma
- 2026-05-26 12:00 EST — [Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza](https://biopharmsignal.com/news/COCP/cocrystal-pharma-announces-discovery-of-pan-viral-inhibitors-targeting-hantaviru-6c5d714e) — Source: Cocrystal Pharma
- 2026-05-15 12:00 EST — [Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/COCP/cocrystal-pharma-provides-business-update-and-reports-first-quarter-2026-financi-f400071b) — Source: Cocrystal Pharma
- 2026-04-30 20:05 EST — [Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection](https://biopharmsignal.com/news/COCP/cocrystal-pharma-presentation-at-icar-2026-highlights-mechanism-of-action-and-cl-398ed2cd) — Source: Cocrystal Pharma